Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by juicyjmillson Feb 28, 2020 7:11pm

169 Views

Post# 30749691

RE:RE:RE:traders sell on news

It seems to me we're only zoomed in on the ants in an anteaters' world - when large corp comes to feast on these great buying conditions (which i believe they are already), these ants wont be so noticeable anymore. In other words, forget the noise of the shaky retail traders who are controlled by irrational primitive instincts. Do your DD on the company, the science, the market, and be anchored like a buoy. The market washes away free floaters during times of high volatility. Once the storm settles you may come to realize that the sharks were too busy feasting below to notice any storm, and ATE is on the menu.

Bullboard Posts

Cross border trading in Canada and Australia